Hims & Hers Health (HIMS) Stock
Direct to consumer telehealth and wellness subscription company. Here's the price, business snapshot, and what's worth knowing about Hims & Hers Health in August 2026.
Hims & Hers Health Inc (HIMS) is a direct‑to‑consumer telehealth and consumer health company offering prescription treatments, over‑the‑counter products and personalised care for sexual health, hair loss, skincare and mental wellbeing. The group combines online consultations, subscription services and product fulfilment to build recurring revenue and scale customer relationships. Investors should note the business is growth‑oriented: expansion of product categories and digital customer acquisition have driven top‑line growth, while profitability can fluctuate with marketing spend, retention rates and regulatory developments. Competition in telehealth and consumer health is strong, and outcomes depend on unit economics and customer lifetime value. Market capitalisation is around $11.16bn. This summary is general educational information, not personal financial advice; it is not a recommendation. Values can rise and fall and returns are not guaranteed — consider suitability, review company filings and consult a qualified financial adviser before investing.
Why You’ll Want to Watch This Stock
Recurring Revenue Focus
Subscriptions and repeat product sales can support predictable revenue, though retention and marketing costs have a strong influence on margins.
Digital‑first Healthcare
Online consultations and streamlined fulfilment enable scale, but regulatory shifts and competitive pressure can affect execution and growth.
Market & Competition
Rising telehealth adoption offers opportunity, while intense competition and pricing pressure mean outcomes can vary between companies.
